My Account
Follow us on:
Powered By
See the top gainers, losers, invest and get updated what's happening in the crypto market
Invest Now
Discover the secret world of unlisted shares — analyse India's top pre-IPO companies and invest before they hit the markets
In an exclusive interview with CNBC-TV18, VVS Murthy, CFO of Dishman Pharma says that the company has announced a consolidated guidance of 21.5-22% EBITDA margins and is expecting 15% growth on a consolidated level for FY12.
You are already a Moneycontrol Pro user.